A meta-analysis of 436 participants, aged 36-60, revealed that psilocybin significantly improved depression scores compared to other treatments, especially in patients with secondary depression
Read Full Article
#PsilocybinResearch #MentalHealth #DepressionTreatment #PsychedelicTherapy #HopeForPatients
Read Full Article
#PsilocybinResearch #MentalHealth #DepressionTreatment #PsychedelicTherapy #HopeForPatients
The BMJ
Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis
Objective To determine the efficacy of psilocybin as an antidepressant compared with placebo or non-psychoactive drugs.
Design Systematic review and meta-analysis.
Data sources Five electronic databases of published literature (Cochrane Central Register…
Design Systematic review and meta-analysis.
Data sources Five electronic databases of published literature (Cochrane Central Register…
❤4💩1
Huntington's disease successfully treated for first time 🎉🧬🩺
Read Full Article
#HuntingtonsDisease #MedicalBreakthrough #GeneticResearch #HopeForPatients #HealthInnovation
Read Full Article
#HuntingtonsDisease #MedicalBreakthrough #GeneticResearch #HopeForPatients #HealthInnovation
Bbc
Huntington's disease successfully treated for first time
One of the most devastating diseases finally has a treatment that can slow its progression and transform lives, tearful doctors tell BBC.
👏2
**Researchers have discovered a novel therapy combination that could offer new hope to ovarian cancer patients 🌸💊. The findings outline a promising strategy that combines a PARP inhibitor with a novel therapy, SM08502, to attack cancer from two directions.**
Read Full Article
#OvarianCancer #CancerResearch #NovelTherapy #PARPInhibitors #HopeForPatients
Read Full Article
#OvarianCancer #CancerResearch #NovelTherapy #PARPInhibitors #HopeForPatients
CU Anschutz Medical Campus
From Lab to Clinic: CU Anschutz Launches Phase 1 Clinical Trial of Promising Combination Therapy for Resistant Ovarian Cancer
From lab to clinic: CU Anschutz launches phase 1 clinical trial of promising combination therapy for resistant ovarian cancer.
👍1
Tofersen, a new drug approved by the FDA for a genetic form of ALS, delays symptom progression and death and in about one-quarter of participants leads to stabilization or improvement. “Stopping disease progression and making improvements over 3 to 5 years is unheard of in this type of ALS.” 🧬💊⏳
Read Full Article
#Tofersen #ALSDisease #FDAApproval #MedicalBreakthrough #HopeForPatients
Read Full Article
#Tofersen #ALSDisease #FDAApproval #MedicalBreakthrough #HopeForPatients
WashU Medicine
New ALS drug stabilizes decline with improved strength, mobility for some | WashU Medicine
Long-term use of tofersen slows ALS disease progression in people with a genetic subtype, provides hope for treating other forms of ALS